10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas trimmed its position in shares of 10x Genomics, Inc. (NASDAQ:TXGFree Report) by 40.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,846 shares of the company’s stock after selling 2,628 shares during the period. Teacher Retirement System of Texas’ holdings in 10x Genomics were worth $215,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. UMB Bank n.a. increased its holdings in shares of 10x Genomics by 51.6% during the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after buying an additional 266 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in 10x Genomics in the 4th quarter valued at $66,000. Van ECK Associates Corp increased its holdings in 10x Genomics by 23.4% in the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock valued at $107,000 after purchasing an additional 362 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in 10x Genomics in the 3rd quarter valued at $146,000. Finally, Powell Investment Advisors LLC acquired a new stake in 10x Genomics in the 4th quarter valued at $200,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at 10x Genomics

In related news, CEO Serge Saxonov sold 4,660 shares of 10x Genomics stock in a transaction on Monday, March 4th. The shares were sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares of the company’s stock, valued at approximately $37,087,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Justin J. Mcanear sold 2,936 shares of 10x Genomics stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $71,344.80. Following the transaction, the chief financial officer now owns 146,203 shares in the company, valued at approximately $3,552,732.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 4,660 shares of 10x Genomics stock in a transaction on Monday, March 4th. The stock was sold at an average price of $44.00, for a total transaction of $205,040.00. Following the completion of the transaction, the chief executive officer now owns 842,900 shares in the company, valued at approximately $37,087,600. The disclosure for this sale can be found here. Insiders sold 16,560 shares of company stock valued at $494,210 in the last quarter. Company insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

10x Genomics stock opened at $22.41 on Friday. The company has a 50 day moving average price of $29.55 and a 200 day moving average price of $40.36. 10x Genomics, Inc. has a 52 week low of $21.74 and a 52 week high of $63.57. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -10.05 and a beta of 1.94.

10x Genomics (NASDAQ:TXGGet Free Report) last issued its earnings results on Tuesday, April 30th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). The company had revenue of $141.01 million during the quarter, compared to analyst estimates of $142.24 million. 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.44) EPS. Equities analysts forecast that 10x Genomics, Inc. will post -1.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TXG has been the subject of several recent research reports. The Goldman Sachs Group lowered their price target on 10x Genomics from $30.00 to $26.00 and set a “sell” rating for the company in a report on Wednesday, May 1st. Bank of America lowered their target price on 10x Genomics from $45.00 to $36.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Stifel Nicolaus lowered their target price on 10x Genomics from $63.00 to $53.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Canaccord Genuity Group lowered their target price on 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 29th. Finally, TD Cowen downgraded 10x Genomics from a “buy” rating to a “hold” rating and lowered their target price for the company from $57.00 to $32.00 in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, 10x Genomics has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Check Out Our Latest Research Report on 10x Genomics

10x Genomics Profile

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGFree Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.